Drug Type CAR-T |
Synonyms AntiMSLN CAR T cell therapy, AntiMSLN chimeric antigen receptor T cell immunotherapy, TMMSTN01 |
Target |
Action inhibitors |
Mechanism MSLN inhibitors(Mesothelin inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Triple Negative Breast Cancer | Phase 1 | United States | 06 Feb 2023 | |
Adenocarcinoma of Lung | Phase 1 | United States | 06 Apr 2017 | |
Fallopian Tube Carcinoma | Phase 1 | United States | 06 Apr 2017 | |
Malignant Mesothelioma of Peritoneum | Phase 1 | United States | 06 Apr 2017 | |
Primary peritoneal carcinoma | Phase 1 | United States | 06 Apr 2017 | |
Recurrent ovarian cancer | Phase 1 | United States | 06 Apr 2017 | |
Mesothelin positive Neoplasms | Phase 1 | United States | 01 Jun 2014 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 01 Jun 2014 | |
Ovarian Serous Tumor | Phase 1 | United States | 01 Jun 2014 | |
Pancreatic adenocarcinoma metastatic | Phase 1 | United States | 01 Jun 2014 |
Phase 1 | 65 | (Cohort 1) | bcbxkmpeze = lcqifyueyt sqomqqezvs (cgihzecljr, hmdunjjobb - axgzbvqdzg) View more | - | 29 Apr 2025 | ||
(Cohort 2) | bcbxkmpeze = uwfqzitine sqomqqezvs (cgihzecljr, fsspfbbjbi - jlwwmfzbfg) View more |